CORTINOVIS DIEGO LUIGI

Gelsomino, F., Boni, L., Tiseo, M., Ricciardi, S., Rocco, D., Cortinovis, D., et al. (2025). An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04–2016. LUNG CANCER, 199(January 2025) [10.1016/j.lungcan.2024.108059]. Dettaglio

Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer. NPJ PRECISION ONCOLOGY, 9(1) [10.1038/s41698-025-01088-0]. Dettaglio

Cortellini, A., Santo, V., Brunetti, L., Garbo, E., Pinato, D., La Cava, G., et al. (2025). Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 13(9) [10.1136/jitc-2025-012423]. Dettaglio

Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) [Altro] [10.1038/s41698-025-01114-1]. Dettaglio

Clementi, T., Colonese, F., Canova, S., Abbate, M., Sala, L., Petrella, F., et al. (2025). Perioperative Chemo/Immunotherapies in Lung Cancer: A Critical Review on the Value of Perioperative Sequences. CURRENT ONCOLOGY, 32(7) [10.3390/curroncol32070397]. Dettaglio